Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01 Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01